This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Renal cancer	Polybromo 1 (PBRM1)	A genomic study suggests that agonizing PBRM1 could help treat clear cell renal carcinoma. In a genomic analysis of tumor tissue from clear cell renal carcinoma patients, 41% contained inactivating mutations in PBRM1. In a clear cell renal cancer cell line, small interfering RNA depletion of <i>PBRM1</i> increased proliferation and cell migration compared with those seen using a scrambled siRNA control. Next steps include identifying therapeutics that modulate the activity of PBRM1.	Patent and licensing status unavailable	Varela, I. <i>et al. Nature</i> ; published online Jan. 19, 2011; doi:10.1038/nature09639 Contact: P. Andrew Futreal, Wellcome Trust Sanger Institute, Hinxton, U.K. e-mail: paf@sanger.ac.uk
SciBX 4(6); doi:10.1038/scibx.2011.163 Published online Feb. 10, 2011				